Biovotion wins Swiss CTI grant

The two groups will bring together extensive expertise and knowledge in high quality wearable monitoring, multivariate data analyses and mHealth eco systems. Biovotion holds internationally recognised expertise and technology in wearable monitoring, supported by an extensive publication track record and IP portfolio. The HES-SO team has extensive international experience on Gestational Diabetes, Diabetes Type 1 and Diabetes Type 2, that was established within the G-DEMANDE and MONDAINE national projects and within COMMODITY2, a European FP7 project.

The project ‘COMPASS’ – Continuous Multi-variate monitoring of patients affected by COPD - aims to create a Personal Health System (PHS) to monitor the physiological parameters of patients affected by e.g. Chronic Obstructive Pulmonary Disease (COPD) and associated chronic illnesses, and predict the physiological state as a support to the decisions taken by medical doctors. COMPASS will achieve this by combining the usage of state-of-the art Biovotion multi-parametric sensors, the Vital Sign Monitoring (VSM) platform, pervasive health, interoperability technology, and machine learning techniques.

Biovotion AG is a Swiss medical device company founded in 2011 and based in Zurich.